HIVACAR aims to provide a new therapeutic alternative to “cART for life” (combined antiretroviral therapy) and will address the individual and public health limitations associated with this standard of care:
- Cost of the medication.
- Mandatory high adherence to medication for life.
- Side effects.
- Risk of resistances developement.
An innovative strategy based on the patient’s immune system, safe, affordable and scalable to achieve the functional cure of HIV-1 infection will be tested in a Phase I / IIa clinical trial. In addition, the ethical, economic and psychosocial challenges associated with a functional HIV cure will be investigated to provide a complementary alternative to the current treatment standard.
A community-led psychosocial survey about HIV remission aims to assess the knowledge and expectations among people living with HIV
Are you a person living with #HIV based in Belgium, Denmark, France or Spain? The European AIDS Treatment Group (EATG), HIV community partner within the #HIVACAR initiative, invites you to fill in 𝙖 𝙨𝙪𝙧𝙫𝙚𝙮 to help better understand 𝙮𝙤𝙪𝙧 𝙠𝙣𝙤𝙬𝙡𝙚𝙙𝙜𝙚 𝙖𝙗𝙤𝙪𝙩 𝙃𝙄𝙑 𝙧𝙚𝙢𝙞𝙨𝙨𝙞𝙤𝙣...
Currently, over 36 million people worldwide are infected with HIV, most of them living in developing countries1. In 2014, 1.2 million people died of AIDS-related illnesses…